Company Directory - Teva Pharmaceuticals
Company Details - Teva Pharmaceuticals
Teva Pharmaceuticals
WebsitePetah Tikva, Israel
Teva Pharmaceuticals is an Israeli multinational pharmaceutical company specializing in generic medications and a broad array of specialty medicines. With a commitment to enabling access to quality healthcare, Teva plays a significant role in improving patients' lives globally.
CCI Score
CCI Score: Teva Pharmaceuticals
-21.90
0.01%
Latest Event
Teva’s Supply Chain Risk: Forced Labor in XUAR
A C4ADS report highlights the persistent reliance on active pharmaceutical ingredients manufactured in Xinjiang under forced labor conditions. This situation raises concerns over the ethical robustness of global pharmaceutical supply chains and implies potential risks for companies like Teva Pharmaceuticals.
Take Action
So what can you do? It's time to make tough choices. Where will you cast your vote?
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
ACCOMPLICE
Teva Pharmaceuticals is currently rated as an Accomplice.
Latest Events
- OCT082024
A C4ADS report highlights the persistent reliance on active pharmaceutical ingredients manufactured in Xinjiang under forced labor conditions. This situation raises concerns over the ethical robustness of global pharmaceutical supply chains and implies potential risks for companies like Teva Pharmaceuticals.
-70
Supply Chain Ethics
April 9
The report describes how forced labor in the Xinjiang Uyghur Autonomous Region is entwined with the production of key pharmaceutical ingredients. This not only perpetuates human rights abuses and supports repressive state practices, but also places companies that may rely on these supply chains, such as Teva Pharmaceuticals, at ethical and reputational risk.
- MAY142024
Teva Pharmaceuticals USA Inc. has filed with the Federal Election Commission to operate its Political Action Committee (Teva PAC). The filing details the committee’s designation as a Lobbyist/Registrant PAC, includes administrative information such as the mailing address in Washington, DC, and names the treasurer. The filing, recorded on May 14, 2024, underscores the company’s engagement in structured political influence activities.
-40
Political Contributions and Lobbying Efforts
April 9
The filing of a Political Action Committee by Teva Pharmaceuticals indicates an organized effort to influence political outcomes through corporate funding channels. While the document does not explicitly tie the PAC to far‐right or authoritarian candidates, corporate PAC activities are generally viewed with skepticism from an anti‐authoritarian perspective since they often serve to reinforce business interests over public accountability, potentially undermining progressive reforms.
TEVA PHARMACEUTICALS USA INC. POLITICAL ACTION COMMITTEE (TEVA PAC) - committee overview
- JAN012024
An OpenSecrets profile reveals that in the 2024 cycle, Teva Pharmaceuticals spent $2.25 million on lobbying while contributing $108,729, and that a significant portion of its lobbyists are former government officials, indicating a strong revolving door phenomenon.
-50
Political Contributions and Lobbying Efforts
April 9
Teva Pharmaceuticals’ disproportionate lobbying expenditure relative to its political contributions, combined with its extensive revolving door ties, indicates a worrisome level of corporate influence on policy. Such behavior can undermine democratic processes and contribute to an authoritarian alignment.
Teva Pharmaceutical Industries Profile: Summary • OpenSecrets
-50
Executive Political Engagement
April 9
The data indicates that a significant proportion of Teva’s lobbyists have prior government experience (4 out of 6 in 2023 and 6 out of 10 in 2024), embodying a revolving door practice that can entrench corporate access to power and further influence policymaking in ways that may favor authoritarian policies.
Teva Pharmaceutical Industries Profile: Summary • OpenSecrets
- DEC312023
Teva Pharmaceutical Industries spent $2,130,000 on lobbying activities during 2023, with details visible on the OpenSecrets lobbying profile.
-40
Political Contributions and Lobbying Efforts
April 9
Teva's use of over $2 million in lobbying reflects a significant investment in influencing public policy. From an anti-fascist perspective, such heavy corporate political spending raises concerns about disproportionate influence over democratic processes and policy outcomes.
Teva Pharmaceutical Industries Lobbying Profile • OpenSecrets
- DEC312023
Teva Pharmaceutical Industries spent $2,130,000 on federal lobbying in 2023 as reported by OpenSecrets, highlighting its active engagement in political influence efforts.
-50
Political Contributions and Lobbying Efforts
April 9
Teva's use of over two million dollars in lobbying expenditure indicates significant corporate involvement in attempting to influence political decision-making. From an anti-fascist perspective, such activities risk undermining democratic transparency and accountability by channeling corporate funds to sway policy in ways that favor business interests over broader public welfare.
- OCT012023
Teva Pharmaceuticals highlights its commitment to an ethical and sustainable supply chain, working with over 48,000 suppliers and supporting a US Supplier Diversity program that offers business opportunities to small and diverse organizations.
+70
Supply Chain Ethics
April 9
The article details Teva's proactive steps to maintain a responsible and sustainable supply chain by working with a large network of suppliers and promoting supplier diversity through its US program. This demonstrates a commitment to ethical sourcing and corporate responsibility, aligning with anti-authoritarian business practices that protect marginalized groups.
- JUN092023
Teva Pharmaceuticals agreed to a $523 million settlement as part of nationwide opioid litigation. The settlement requires Teva to operate under a monitor, ban opioid marketing, and implement stricter safeguards, a measure aimed at holding the company accountable for its role in the opioid crisis as announced by New York Attorney General Letitia James on June 9, 2023.
+60
Business Practices and Ethical Responsibility
April 9
The settlement forces Teva Pharmaceuticals to address its harmful business practices related to opioid distribution, requiring oversight and prohibition of opioid marketing. Such accountability measures promote ethical business practices and protect public health, aligning with progressive, anti-authoritarian principles by holding corporations liable for their actions.
+40
Economic and Structural Influence
April 9
The financial penalty and oversight measures imposed on Teva represent a significant check on the company’s economic influence. By redirecting funds for opioid abatement, treatment, and prevention, the settlement mitigates corporate power and reinforces accountability, contributing positively to economic and structural reforms for marginalized communities.
- JAN012023Teva PAC Overview
0.00
An official record on the FEC website confirms the existence of Teva Pharmaceuticals USA Inc.'s Political Action Committee (Teva PAC). The record details the connected organization without attributing any explicit far‐right or authoritarian political agenda.
+0
Political Contributions and Lobbying Efforts
April 9
The FEC record shows that Teva Pharmaceuticals maintains a PAC to handle political contributions. However, there is no evidence in the article that the PAC is used to promote far‐right or authoritarian policies, leading to a neutral score on political contributions and lobbying efforts.
TEVA PHARMACEUTICALS USA INC. POLITICAL ACTION COMMITTEE (TEVA PAC) - committee overview
- JAN012023
Teva Pharmaceutical Industries Limited has agreed to a settlement paying over $519 million to resolve civil and criminal charges that it violated the Foreign Corrupt Practices Act by bribing foreign officials in Russia, Ukraine, and Mexico to secure regulatory and market advantages.
-60
Public and Political Behavior
April 9
Teva's engagement in bribery to influence regulatory approvals and drug formulary decisions undermines democratic processes and transparency, reflecting behavior that aligns with authoritarian practices by subverting fair market and political processes.
-80
Business Practices and Ethical Responsibility
April 9
The settlement highlights significant unethical business practices by Teva, where deliberate bribery was used for commercial advantage. This behavior not only violates legal standards but also erodes public trust and contributes to a corporate culture that may support authoritarian interests.
- JAN012023
The FEC data page highlights the existence of Teva Pharmaceuticals USA Inc.'s Political Action Committee (Teva PAC), an instrument through which the company engages in political contributions and lobbying efforts.
-10
Political Contributions and Lobbying Efforts
April 9
Teva Pharmaceuticals’ operation of a Political Action Committee indicates routine corporate political engagement that may be used to influence policy outcomes. From an anti-fascist perspective, such mechanisms are concerning due to their potential to undercut accountability and democratic processes, even though no specific far‑right or authoritarian alignment is detailed in the source.
TEVA PHARMACEUTICALS USA INC. POLITICAL ACTION COMMITTEE (TEVA PAC) - committee overview
- AUG182020
The United States Department of Justice filed a False Claims Act complaint against Teva Pharmaceuticals, alleging that the company funneled payments through ostensibly independent charitable foundations to cover Medicare co-pays for its MS drug Copaxone, while simultaneously increasing the drug’s price significantly. The complaint alleges the scheme amounted to illegal kickbacks that undermined the Medicare co-pay system and exploited taxpayers.
-70
Business Practices and Ethical Responsibility
April 9
This rating reflects significant breaches in ethical business practices as Teva is accused of using charitable foundations as conduits for kickbacks, thereby inflating drug prices and misusing funds meant for patient assistance. Such practices undermine trust in the pharmaceutical industry and distort market dynamics to the detriment of public welfare.
-30
Economic and Structural Influence
April 9
The alleged scheme not only breaches ethical practices but also exerts harmful economic and structural influence. By driving up drug prices and mismanaging funds intended for patient support, Teva’s conduct disrupts the integrity of public healthcare funding and burdens taxpayers, thereby having negative structural implications.
Alternatives
Barcelona, Spain
57.57
Japan
26.16
Bagsværd, Denmark
18.81
Kenilworth, United States
2.89
Tokyo, Japan
-7.42
Basel, Switzerland
-19.75
North Chicago, United States
-31.53
Indianapolis, United States
-35.34
Hyderabad, India
-53.10
Corporation
2.31
Corporate Financials
- Revenue
- 2023
- $15.60B
- Total Assets
- 2023
- $35.60B
- Operating Income
- 2023
- $5.80B
- Total Equity
- 2023
- $7.00B
Employees: 38,000
Industries
- 325411
- Medicinal and Botanical Manufacturing
- 325412
- Pharmaceutical Preparation Manufacturing
- 541713
- Research and Development in Nanotechnology